(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $6.41
発行日: 15 2月 2024 @ 04:41
リターン: -25.97%
前回のシグナル: 2月 15 - 03:57
前回のシグナル:
リターン: 2.72 %
Live Chart Being Loaded With Signals
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology...
Stats | |
---|---|
本日の出来高 | 3.88M |
平均出来高 | 2.47M |
時価総額 | 705.24M |
EPS | $0 ( 2024-03-11 ) |
次の収益日 | ( $-0.180 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.65 |
ATR14 | $0.0100 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-26 | Summer Road Llc | Buy | 930 851 | Common Stock, $0.0001 par value per share |
2024-02-22 | Dugel Pravin | Buy | 1 282 469 | Stock Option (Right to Buy) |
2024-02-22 | Dugel Pravin | Buy | 854 979 | Common Stock |
2024-02-22 | Nayak Sanjay | Buy | 244 550 | Stock Option (Right to Buy) |
2024-02-22 | Nayak Sanjay | Buy | 80 300 | Common Stock |
INSIDER POWER |
---|
97.80 |
Last 98 transactions |
Buy: 9 847 283 | Sell: 256 052 |
ボリューム 相関
Ocular Therapeutix Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Ocular Therapeutix Inc 相関 - 通貨/商品
Ocular Therapeutix Inc 財務諸表
Annual | 2023 |
収益: | $58.44M |
総利益: | $53.16M (90.96 %) |
EPS: | $-1.010 |
FY | 2023 |
収益: | $58.44M |
総利益: | $53.16M (90.96 %) |
EPS: | $-1.010 |
FY | 2022 |
収益: | $51.49M |
総利益: | $46.95M (91.18 %) |
EPS: | $-0.830 |
FY | 2021 |
収益: | $43.52M |
総利益: | $39.12M (89.88 %) |
EPS: | $-0.0900 |
Financial Reports:
No articles found.
Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。